Identification of biomarkers for patients with diffuse low-grade glioma

Gliomas are the most common type of primary brain tumors and consist of low- and high-grade gliomas. Low-grade gliomas in adults are called diffuse low-grade gliomas (DLGG).

DLGG are tumors with malignancy grade II according to the WHO classification of brain tumors, constituting an “interface” between benign and malignant tumors. DLGG have an annual incidence of 1.5-1.8 per 100 000 inhabitants and commonly occur as astrocytomas, oligodendrogliomas or oligoastrocytomas grade II. In spite of a relatively favorable prognosis (5-year survival rate of 50-80%), most if not all DLGG will eventually develop into malignant gliomas with fatal outcome. Treatment consists of a combination of surgery, radiotherapy and chemotherapy, but the most effective therapeutic modality as well as the optimal timing of treatment is still a matter of debate. This dilemma is strongly related to the variety in natural course of disease and response to therapy between individual patients.

Our clinical studies focus on the application of advanced MRI in combination with11C-methionine PET for preoperative evaluation of DLGG, to detect early tumor progression and to monitor response to treatment. We are particularly interested in evaluating these results with respect to cognitive functions and neurological symptoms such as epileptic seizures during the course of disease.

Translational studies consist of affinity-based proteomics on tissue samples of DLGG, where we evaluate specific protein profiles of the tumor in correlation to clinical parameters such as response to therapy and survival. The overall aim of is to identify diagnostic, predictive and prognostic biomarkers that can guide clinical decisions and provide better opportunities for individualized treatment. In a longer perspective, our studies may provide a ground for new therapeutic targets and individually based treatment.

From left; Shala Ghaderi Berntsson and Anja Smits

Group members:

Anja Smits, MD, PhD, Prof

Shala Ghaderi Berntsson, MD, PhD

Tamador Elsir, PhD

Krisztina Szalisznyo, MD, PhD

Maria Zetterlin MD, PhD

Kenney Roodakker PhD-student

Contact

Group leader:

Prof. Anja Smits

E-mail: anja.smits@neuro.uu.se

 

Viktig forskning om Lågmaligna gliom

Från Institutionen för neurovetenskaps interna nyhetsbrev, Läs artikeln här text & bild: Cecilia Yates

läs mer om om forskningen..

Läs hela artikeln i DN där Anja Smits, Shala Berntson och Maria Zetterling medverkar, "Individuell behandling av lågmalignt gliom- målet för hängivna forskare", DN 24 Sep 2012